Lundh, Stefan

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 1,785

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 862

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

Ghassemi, S., Nunez-Cruz, S., O'Connor, R. S., Fraietta, J. A., Patel, P. R., Scholler, J., Barrett, D. M., Lundh, S. M., Davis, M. M., Bedoya, F., et al. (2018) · Cancer Immunology Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 312

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL

Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 166